Global Regenerative Medicine Market Research Report 2020

DUBLIN, Dec. 4, 2020 /PRNewswire/ — The “Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography – Global Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering.

The Global Regenerative Medicine Market is Projected to Reach USD 17.9 Billion by 2025 from USD 8.5 Billion in 2020, at a CAGR of 15.9% during the Forecast Period.

Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products. However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period.

The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast period

Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Oncology segment accounted for highest CAGR

Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the oncology segment accounted for the highest growth rate. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Prevalence of Chronic Diseases, Genetic Disorders, and Cancer
5.2.1.2 Rising Investments in Regenerative Medicine Research
5.2.1.3 Growing Pipeline of Regenerative Medicine Products
5.2.2 Restraints
5.2.2.1 Ethical Concerns Related to the Use of Embryonic Stem Cells in Research & Development
5.2.2.2 High Cost of Cell and Gene Therapies
5.2.3 Opportunities
5.2.3.1 Implementation of the 21st Century Cures Act
5.2.3.2 Rising Demand for Organ Transplantations
5.3 Impact of the COVID-19 Pandemic on the Regenerative Medicine Market

6 Regenerative Medicine Market, by Product
6.1 Introduction
6.2 Tissue-Engineered Products
6.2.1 Rising Prevalence of Chronic Wounds to Drive the Market Growth
6.3 Cell Therapies
6.3.1 Autologous Therapies
6.3.1.1 Autologous Therapies Segment to Register the Highest Growth in the Cell Therapies Market
6.3.2 Allogeneic Therapies
6.3.2.1 Rising Incidence of Chronic Conditions to Drive the Market Growth
6.4 Gene Therapies
6.4.1 Growing Number of Cancer Cases to Drive Market Growth
6.5 Progenitor & Stem Cell Therapies
6.5.1 Growing Product Pipeline to Support the Growth of this Segment

Read more

Intermediate embryonic stem cell type could lead to advances in regenerative medicine

A team led by UT Southwestern has derived a new “intermediate” embryonic stem cell type from multiple species that can contribute to chimeras and create precursors to sperm and eggs in a culture dish.

The findings, published online this week in Cell Stem Cell, could lead to a host of advances in basic biology, regenerative medicine, and reproductive technology.

Cells in early embryos have a range of distinct pluripotency programs, all of which endow the cells to create various tissue types in the body, explains study leader Jun Wu, Ph.D., assistant professor of molecular biology.

A wealth of previous research has focused on developing and characterizing “naïve” embryonic stem cells (those about four days post-fertilization in mice) and “primed” epiblast stem cells (about seven days post-fertilization in mice, shortly after the embryo implants into the uterus).

However, says Wu, there’s been little progress in deriving and characterizing pluripotent stem cells (PSCs) that exist between these two stages – largely because researchers have not been able to develop a paradigm for maintaining cells in this intermediate state.

Cells in this state have been thought to possess unique properties: the ability to contribute to intraspecies chimeras (organisms that contain a mix of cells from different individuals of the same species) or interspecies chimeras (organisms that contain a mix of cells from different species) and the ability to differentiate into primordial germ cells in culture, the precursors to sperm and eggs.

For this study, the researchers successfully created intermediate PSCs, which they named “XPSCs” from mice, horses, and humans.

Wu says that these results could eventually lead to an array of advances in both basic and applied research. For example, looking at gene activity in XPSCs from different species and interspecies chimeras could help researchers understand which signatures have been conserved through evolution.

Examining the communication between cells in chimeras may help scientists identify strategies that could be used to accelerate the development of tissues and organs from stem cells used for transplantation.

And using chimera-derived primordial germ cells to create sperm and eggs could aid in preserving endangered animal species and advancing infertility treatments.

These XPSCs have enormous potential. Our study helps open the door to each of these possibilities.”


Jun Wu, PhD, Study Leader and Assistant Professor of Molecular Biology, Virginia Murchison Linthicum Scholar in Medical Research, UT Southwestern Medical Center

Wu notes that developing XPSCs presented a special challenge because the conditions that keep naïve PSCs in a stable state are exactly the opposite of those that stabilize primed PSCs.

While culture conditions for naïve PSCs must activate a WNT cell-signaling pathway and suppress the FGF and TGF-ß pathways, the conditions to maintain primed PSCs must suppress WNT and activate FGF and TGF-ß.

Aiming for the preferred environment for XPSC derivation, Wu and his colleagues placed cells from early mouse embryos into cultures containing chemicals and growth factors that activate all three pathways.

These lab-grown cells were extremely stable in culture and able to multiply

Read more

Development of new stem cell type may lead to advances in regenerative medicine

IMAGE

IMAGE: Drs. Jun Wu, Leqian Yu, Yulei Wei and colleagues isolated a new type of pluripotent stem cell from mice, horses, and humans, named XPSCs, which are capable of generating chimeras…
view more 

Credit: Photo illustration by Leqian Yu

DALLAS – Dec. 3, 2020 – A team led by UT Southwestern has derived a new “intermediate” embryonic stem cell type from multiple species that can contribute to chimeras and create precursors to sperm and eggs in a culture dish.

The findings, published online this week in Cell Stem Cell, could lead to a host of advances in basic biology, regenerative medicine, and reproductive technology.

Cells in early embryos have a range of distinct pluripotency programs, all of which endow the cells to create various tissue types in the body, explains study leader Jun Wu, Ph.D., assistant professor of molecular biology. A wealth of previous research has focused on developing and characterizing “naïve” embryonic stem cells (those about four days post-fertilization in mice) and “primed” epiblast stem cells (about seven days post-fertilization in mice, shortly after the embryo implants into the uterus).

However, says Wu, there’s been little progress in deriving and characterizing pluripotent stem cells (PSCs) that exist between these two stages – largely because researchers have not been able to develop a paradigm for maintaining cells in this intermediate state. Cells in this state have been thought to possess unique properties: the ability to contribute to intraspecies chimeras (organisms that contain a mix of cells from different individuals of the same species) or interspecies chimeras (organisms that contain a mix of cells from different species) and the ability to differentiate into primordial germ cells in culture, the precursors to sperm and eggs.

For this study, the researchers successfully created intermediate PSCs, which they named “XPSCs” from mice, horses, and humans.

Wu says that these results could eventually lead to an array of advances in both basic and applied research. For example, looking at gene activity in XPSCs from different species and interspecies chimeras could help researchers understand which signatures have been conserved through evolution. Examining the communication between cells in chimeras may help scientists identify strategies that could be used to accelerate the development of tissues and organs from stem cells used for transplantation. And using chimera-derived primordial germ cells to create sperm and eggs could aid in preserving endangered animal species and advancing infertility treatments.

“These XPSCs have enormous potential. Our study helps open the door to each of these possibilities,” says Wu, who is a Virginia Murchison Linthicum Scholar in Medical Research.

Wu notes that developing XPSCs presented a special challenge because the conditions that keep naïve PSCs in a stable state are exactly the opposite from those that stabilize primed PSCs. While culture conditions for naïve PSCs must activate a WNT cell-signaling pathway and suppress the FGF and TGF-ß pathways, the conditions to maintain primed PSCs must suppress WNT and activate FGF and TGF-ß.

Aiming for the preferred environment for XPSC derivation, Wu and his

Read more

Regenerative Medicine Market measure with Report In Depth Industry Analysis on Trends, Growth, Opportunities and Forecast till 2026

The MarketWatch News Department was not involved in the creation of this content.

Dec 02, 2020 (Market Insight Reports) —
The latest report on ‘Regenerative Medicine market’ collated by Market Study Report, LLC, delivers facts and numbers regarding the market size, geographical landscape and profit forecast of the ‘Regenerative Medicine market’. In addition, the report focuses on major obstacles and the latest growth plans adopted by leading companies in this business.

Request a sample Report of Regenerative Medicine Market at: https://www.marketstudyreport.com/request-a-sample/1695290?utm_source=marketwatch&utm_medium=RV

The Regenerative Medicine Market is anticipated to reach over USD 79.23 billion by 2026 according to a new research. In 2017, the cell therapy dominated the global Regenerative Medicine market, in terms of revenue. North America is expected to be the leading contributor to the global market revenue in 2017.

The regenerative medicine market is primarily driven by the increasing number of individuals suffering from cancer, rising need to monitor and treating these chronic diseases in the limited time. Furthermore, stringent government policies, proper reimbursement policies, and increasing government healthcare expenditure for developing healthcare infrastructure to also boost the market growth in coming years. Also, rising number of organ transplantation, and increasing number of products in pipeline that are waiting for approval create major opportunity for the regenerative medicines in the coming years. However, some of the ethical and religious concerns for the use of stem cells, and lack of proper regulatory for the approval of various drugs would impede the market growth during the forecast period.

Enquiry about Regenerative Medicine market report before Buying at: https://www.marketstudyreport.com/enquiry-before-buying/1695290?utm_source=marketwatch&utm_medium=RV

North America generated the highest revenue in the Regenerative Medicine market in 2017, and is expected to be the leading region globally during the forecast period. Increasing number of patients suffering from chronic diseases, improved healthcare infrastructure and health facilities, accessibility of healthcare facilities, are the primary factors driving the market growth in this region. While, Asia Pacific to be the fastest growing region in the coming years. The growth in this region is majorly attributed to the developing healthcare infrastructure of the countries like India, & China, and rising awareness for the use of regenerative medicines as an effective treatment option for chronic diseases.

Regenerative medicine is a branch of medicine that regrows, and repairs the damaged cells in the human body. These medicines include the use of stem cells, tissue engineering, that further helps in developing new organ that function smoothly. These medicines have the caliber of developing an entire organ as these cells are multipotent. The cells are majorly isolated from bone marrow, and umbilical cord blood.

Purchase full report of Regenerative Medicine market at: https://www.marketstudyreport.com/securecheckout/paymenta/1695290?utm_source=marketwatch&utm_medium=RV?msfpaycode=sumsf

The key players operating in the Regenerative Medicine market include Organogenesis Inc., Vericel Corporation, Osiris Therapeutics, Inc., Stryker Corporation, and NuVasive, Inc., Medtronic Plc., Acelity, Cook Biotech Inc., Integra LifeSciences, and C.R. Bard. These companies launch new products and collaborate with other market leaders to innovate and launch new products to meet the increasing needs and requirements of consumers.

Regenerative Medicine Market share

Read more

Regenerative Medicine Market Size, Share to Amass Significant Gains During 2020-2025 – Industry News

The MarketWatch News Department was not involved in the creation of this content.

Dec 01, 2020 (Market Insight Reports) —
Selbyville, Delaware. The report Regenerative Medicine Market Size and Analysis maintains enhanced dynamics and is overshadowed by a top player across the globe. The research report provides Regenerative Medicine Market Growth and information corresponding to market segments such as geographies, product type, application, and end-use industry. Experts use the most recent Regenerative Medicine Market research techniques and tools to assemble widespread and precise marketing research reports. A detailed outline about Regenerative Medicine market size and share were combined in this report which gives a comprehensive analysis of different verticals of businesses.

The prevalence of diseases Alzheimera??s, diabetes and other chronic disorders is higher among the aging population across the globe. The incidence of diseases is getting increased day by day among the population. According to the Alzheimera??s Association, it is the 6th leading cause in the United States in 2020 and around 5 million individuals are living with Alzheimera??s. The use of regenerative medicine is getting popular and offers a complete cure from the disease. According to research report a??Global Regenerative Medicine Market Analysis, 2020a??, the Global Regenerative Medicine market is anticipated to grow at a CAGR of around 21.5% during 2020-25.

Request a sample Report of Regenerative Medicine Market [email protected] https://www.marketstudyreport.com/request-a-sample/2767182/?utm_source=marketwatch.com&utm_medium=ADS

Global Regenerative Medicine Market Analysis, 2020 research report depicts a deep dive market analysis of statistics of Global Regenerative Medicine market which consists of regional and country-wise market size, forecast, CAGR market segmentation, market shares of diverse regions and countries, market share of various end-users, applications, product type, technologies, competitive benchmarking, etc.

Pharmaceutical Remains a Dominant Sector

The pharmaceutical sector witnessed immense growth opportunities as more and more companies are indulging in research and studies for regenerative medicine in 2019. Vertex Pharmaceuticals Incorporated in 2018 got approval by FDA for launching their third medicine SYMDEKO for cystic fibrosis (CF) which is a genetic disorder affects liver, kidneys, pancreas, intestine, and lungs. These developments are propelling the growth of regenerative medicine and are expected to witness bolstering demand through 2025 as revealed by the research report a??Global Regenerative Medicine Market Analysis, 2020a??.

Musculoskeletal Disorders is Gaining Pace Across the Globe

The rising occurrence of arthritis and orthopedic diseases among the aging population as well as in the young population. Therefore, musculoskeletal disorders grabbed the largest market share in 2019. Moreover, diseases such as diabetes are also common in the Asian subcontinent. Moreover, around 34.2 million people of all ages or 10.5% of the US population had diabetes in 2018. Approximately, 34.1 million adults aged 18 years or older or 13.0% of all US adults had diabetes, according to US National Diabetes Statistics.

According to the key players with a considerable market share in the Global Regenerative Medicine market include Novartis AG, Vericel, Stryker, Spark Therapeutics, Wright Medical, Pfizer, Abbott, Astra Zenca Ltd., Astellas Pharma Inc., Osiris Therapeutics, Mimedx Group, Organogenesis Inc., Athersys, Inc, Acelity Holdings, Inc, etc.

Key Questions

Read more

Regenerative Medicine Market Futuristic Comprehensive Insights with COVID-19 Impact Analysis | Organogenesis Inc, Osiris Therapeutics Inc

The MarketWatch News Department was not involved in the creation of this content.

Nov 29, 2020 (MarketResearch.biz via Comtex) —
A consciously conceived and designed business intelligence report titled Global Regenerative Medicine market 2020 by Manufacturers, Type, and Application, Forecast to 2029 by MarketResearch.biz discloses a succinct analysis of the regional spectrum, market size, and revenue forecast about the market. This report sheds light on the vital developments along with other events happening in the global Regenerative Medicine market which is marking on the enlargement and opening doors for outlook growth in the coming years.

This is the latest report, covering the current COVID-19/Corona Virus pandemic impact on the market which has affected every aspect of life globally. This has brought along several changes in market conditions and the Business areas. The rapidly changing market scenario and initial and future assessment of the impact are covered in the Regenerative Medicine market report. 

For All-Inclusive Information: Download a FREE sample copy of Regenerative Medicine Market Report Study 2020-2029 at https://marketresearch.biz/report/regenerative-medicine-market/request-sample

(Our FREE SAMPLE COPY of the report gives a brief introduction to the research report outlook, list of tables and figures, Impact Analysis of COVID-19, TOC, an outlook to key players of the market and comprising key regions.)

Competitive Analysis:

The major companies are exceedingly focused on innovation in Regenerative Medicine production technology to enhance ledge life and efficiency. The best long-term development path for Regenerative Medicine market can be caught by guaranteeing financial pliancy to invest in the optimal strategies and current process improvement.

Key manufacturers are included based on the company profile, sales data and product specifications, etc: Organogenesis Inc, Osiris Therapeutics Inc, Pfizer Inc, Novartis AG, Vericel Corporation, NuVasive Inc, Cook Biotech Inc, GlaxoSmithKline plc., Boehringer Ingelheim GmbH, Amgen Inc

Each manufacturer or Regenerative Medicine market player’s growth rate, gross profit margin, and revenue figures is provided in a tabular, simple format for few years and an individual section on Regenerative Medicine market recent development such as collaboration, mergers, acquisition, and any new service or new product launching in the market is offered.

Regenerative Medicine Market Segmentation Outlook By therapy, product type, application, and region:

By therapy: Cell Therapy Tissue Engineering Immunotherapy Gene Therapy By product type: Cell-Based Products Allogeneic Products Autologous Products Acellular Products By application: Orthopedic & Musculoskeletal Disorders Dermatology Cardiology Dermatology Diabetes Central Nervous System Disorders Others

Download Now And Browse Complete Information On The COVID 19 Impact Analysis On Regenerative Medicine Market: https://marketresearch.biz/report/regenerative-medicine-market/covid-19-impact

Regional Analysis:On the idea of geography, the Regenerative Medicine Market report covers statistics for a couple of geographies inclusive of, North America (U.S., Mexico, Canada) South America (Argentina, Brazil) The Middle East & Africa (South Africa, Saudi Arabia) Asia-Pacific (China, Japan, India, Southeast Asia) Europe (U.K., Spain, Italy, Germany, France, Russia)

In addition, The following years considered for this study to forecast the global Regenerative Medicine market size are as follows:

– Actual Year: 2019

– Estimated Year: 2020

– Forecast Year: 2020–2029

Some Fundamental Report Highlights:

– Thorough Outline

Read more

Regenerative Medicine Market 2020 Global Trends Evaluation, Geographical Segmentation, and Investment Opportunities till 2026

The MarketWatch News Department was not involved in the creation of this content.

Nov 25, 2020 (AmericaNewsHour) —
The Regenerative Medicine Market report provides an in-depth analysis of the Healthcare & Pharmaceuticals during the forecast period 2017-2026 which consists of the industry overview including the market size, volume, growth rate and recent trends and developments in the market based on historical and current data. The report covers detailed information about the key players, market segments, growth drivers and restraints in the industry. The report delivers an insight into the Regenerative Medicine Market which allows our clients to make informed decisions regarding the growth of their businesses.

The Regenerative Medicine Market is anticipated to reach over USD 79.23 billion by 2026 according to a new research published by Polaris Market Research. In 2017, the cell therapy dominated the global Regenerative Medicine market, in terms of revenue. North America is expected to be the leading contributor to the global market revenue in 2017.
Regenerative medicine is a branch of medicine that regrows, and repairs the damaged cells in the human body. These medicines include the use of stem cells, tissue engineering, that further helps in developing new organ that function smoothly. These medicines have the caliber of developing an entire organ as these cells are multipotent. The cells are majorly isolated from bone marrow, and umbilical cord blood.

Download free Sample of This Strategic Report:- https://www.kennethresearch.com/sample-request-10070801

The regenerative medicine market is primarily driven by the increasing number of individuals suffering from cancer, rising need to monitor and treating these chronic diseases in the limited time. Furthermore, stringent government policies, proper reimbursement policies, and increasing government healthcare expenditure for developing healthcare infrastructure to also boost the market growth in coming years. Also, rising number of organ transplantation, and increasing number of products in pipeline that are waiting for approval create major opportunity for the regenerative medicines in the coming years. However, some of the ethical and religious concerns for the use of stem cells, and lack of proper regulatory for the approval of various drugs would impede the market growth during the forecast period.

North America generated the highest revenue in the Regenerative Medicine market in 2017, and is expected to be the leading region globally during the forecast period. Increasing number of patients suffering from chronic diseases, improved healthcare infrastructure and health facilities, accessibility of healthcare facilities, are the primary factors driving the market growth in this region. While, Asia Pacific to be the fastest growing region in the coming years. The growth in this region is majorly attributed to the developing healthcare infrastructure of the countries like India, & China, and rising awareness for the use of regenerative medicines as an effective treatment option for chronic diseases.

The key players operating in the Regenerative Medicine market include Organogenesis Inc., Vericel Corporation, Osiris Therapeutics, Inc., Stryker Corporation, and NuVasive, Inc., Medtronic Plc., Acelity, Cook Biotech Inc., Integra LifeSciences, and C.R. Bard. These companies launch new products and collaborate with other market leaders

Read more

Global Regenerative Medicine Market 2020-2025: Opportunities with the Implementation of the 21st Century Cures Act

Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) — The “Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography – Global Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering.

The Global Regenerative Medicine Market is Projected to Reach USD 17.9 Billion by 2025 from USD 8.5 Billion in 2020, at a CAGR of 15.9% during the Forecast Period.

Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products. However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period.

The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast period

Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Oncology segment accounted for highest CAGR

Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the oncology segment accounted for the highest growth rate. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

Europe: The fastest-growing region regenerative medicine market

The global regenerative medicine market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. The North America region is projected to grow at the highest CAGR during the forecast period in 2019. The growth in the North American regenerative medicine market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

Market Dynamics

Drivers

  • Rising Prevalence of Chronic Diseases, Genetic Disorders, and Cancer
  • Rising Investments in Regenerative Medicine Research
  • Growing Pipeline of Regenerative Medicine Products

Restraints

  • Ethical Concerns Related to the Use of Embryonic Stem Cells in Research & Development
  • High Cost of Cell and Gene Therapies

Opportunities

  • Implementation of the 21st Century Cures Act
  • Rising Demand for Organ Transplantations

Impact of the COVID-19 Pandemic on the Regenerative Medicine Market

Companies Mentioned

  • 3M Group
  • Allergan
  • Amgen, Inc.
  • Anterogen Co., Ltd.
  • APAC Biotech
  • Aspect Biosystems
  • Bluebird Bio
  • Corestem, Inc.
  • Integra Lifesciences Holdings Corporation
  • Kite Pharma
Read more

Global Regenerative Medicine Market 2020-2025: Opportunities with the Implementation of the 21st Century Cures Act – Press Release

Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) — The “Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography – Global Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering.

The Global Regenerative Medicine Market is Projected to Reach USD 17.9 Billion by 2025 from USD 8.5 Billion in 2020, at a CAGR of 15.9% during the Forecast Period.

Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products. However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period.

The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast period

Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Oncology segment accounted for highest CAGR

Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the oncology segment accounted for the highest growth rate. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

Europe: The fastest-growing region regenerative medicine market

The global regenerative medicine market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. The North America region is projected to grow at the highest CAGR during the forecast period in 2019. The growth in the North American regenerative medicine market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

Market Dynamics

Drivers

  • Rising Prevalence of Chronic Diseases, Genetic Disorders, and Cancer
  • Rising Investments in Regenerative Medicine Research
  • Growing Pipeline of Regenerative Medicine Products

Restraints

  • Ethical Concerns Related to the Use of Embryonic Stem Cells in Research & Development
  • High Cost of Cell and Gene Therapies

Opportunities

  • Implementation of the 21st Century Cures Act
  • Rising Demand for Organ Transplantations

Impact of the COVID-19 Pandemic on the Regenerative Medicine Market

Companies Mentioned

  • 3M Group
  • Allergan
  • Amgen, Inc.
  • Anterogen Co., Ltd.
  • APAC Biotech
  • Aspect Biosystems
  • Bluebird Bio
  • Corestem, Inc.
  • Integra Lifesciences Holdings Corporation
  • Kite Pharma
  • Medipost
Read more

The Alliance for Regenerative Medicine Announces Record Sector Financing in 2020

The regenerative medicine sector attracted $15.9 billion in financing through just the first three quarters of the year, shattering the previous record of $13.5 billion

Washington, DC – ( NewMediaWire ) – November 19, 2020 – Global financing for the regenerative medicine and advanced therapy sector set an annual record of $15.9 billion through just the first three quarters of 2020, according to  data  released today by the Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines.

Despite the COVID-19 pandemic, financing for the cell, gene, and tissue-based therapies sector surpassed the previous record of $13.5 billion set during full-year 2018.

“There is strength across all types of investment and stages of the pipeline, from early-stage cell-based immuno-oncology to late-stage gene therapies,” said Janet Lambert, CEO of ARM. “The outlook for patients has never been brighter.”

Investors remain bullish about the promise of profound, durable, and possibly curative regenerative medicines to treat a range of diseases and disorders.

Public financing continues to drive the sector, through both IPOs ($2.8 billion YTD) and follow-on financings ($5.7 billion YTD). At $4.1 billion year-to-date, venture capital financing is also on track to surpass the previous record of $4.3 billion set in 2019.

“The rapid advancement of the science behind regenerative medicine makes this a very dynamic time for investors and a hopeful time for patients,” said Jason Rhodes, a partner at Atlas Venture. “The breadth of approaches now available — from CRISPR to CAR-Ts to lentiviruses and non-viral gene therapies — enables us to pick the right tool for the specific biology that we’re addressing.”

Highlights from ARM’s third-quarter 2020 data include:

Gene therapy financing was $3.5B in Q3 2020 and $12 billion YTD, up 178% and 114% from 2019 levels respectively; cell therapy financing reached $3 billion in Q3 2020 and $11 billion YTD, up 97% and 242%, respectively; tissue-based therapy financing was $226 million in Q3 2020 and $311 million YTD, up 11% and 311% respectively.*

At the end of Q3 2020, there were 1,109 regenerative medicine clinical trials ongoing worldwide – 373 in gene therapy, 492 in cell-based immuno-oncology, 202 in cell therapy, and 42 in tissue-based therapies.

Of the 1,109 clinical trials, 388 target more prevalent diseases, including prevalent cancers (159), cardiovascular disease (35), diseases of the central nervous system (33), infectious diseases including COVID-19 (38), and diabetes (17).

There are 97 ongoing Phase 3 clinical trials, with regulatory decisions expected in the coming months in the US and Europe for several product candidates across cell, gene, and tissue-based therapies; cell-based immuno-oncology now comprises more than half of the 418 Phase 1 trials.

There are 1,026 regenerative medicine and advanced therapy developers active globally, up from 1,001 in our previous report covering the first half of 2020. Of the current total, 536 are active in gene therapy, 641 are active in cell therapy, and 135 are active in tissue-based therapies.

* Some companies utilize multiple technology types, and financings for

Read more